Aus firm develop hair test from breast cancer
This article was originally published in Clinica
An Australian firm is developing a test that can detect breast cancer from hair samples. Sydney-based Fermiscan told Clinica that the test could become available in Australia as early as this year, and will be marketed in other countries once the firm has regulatory approval and licensing agreements in place.
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.